Titan Pharmaceuticals, Inc. announced on June 3, 2025, that Black Titan Corporation filed a registration statement on Form F-4 with the U.S. Securities and Exchange Commission (SEC). This filing is in connection with the proposed business combination of Titan and TalenTec Sdn. Bhd., which includes Titan’s preliminary proxy statement. The merger agreement was initially announced on August 19, 2024.
The Form F-4, filed by Black Titan Corporation as the holding company for the combined businesses, is a critical regulatory step for the reverse merger transaction. The registration statement has not yet been declared effective by the SEC, and the information contained within the preliminary proxy statement/prospectus is subject to change.
The business combination remains subject to approval by Titan stockholders and the satisfaction of other customary closing conditions. The company anticipates the merger to close in the third quarter of 2025. This filing signifies substantial progress in Titan's strategic pivot towards its new combined entity.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.